Table 1.
Adverse event rates, event costs and AE management costs.
| Grade 3/4 AEs | AE incidence |
AE unit cost |
||
|---|---|---|---|---|
| LEN/DEX23 | BORT24 | Cost per event (2011 USD) | Cost source | |
| Neutropenia | 33.4% | 14% | $149 (inflated from 2010) | Goulart and Ramsey35 |
| Febrile neutropenia | 2.3% | NR | $11,857 (inflated from 2010) | Goulart and Ramsey35 |
| Thrombocytopenia | 12.2% | 30% | $149 (inflated from 2010) | Goulart and Ramsey35 |
| Anemia | 9.9% | 10% | $869 (inflated from 2010) | Goulart and Ramsey35 |
| PN | NR | 8.00% | $1017 (inflated from 2001) | Calhoun et al.36 |
| DVT/PEa | 2.05% | NR | $28,343 (inflated from 2002) | Elting et al.37 |
| Diarrhea | 3.1% | 7% | $2733 (inflated from 2003) | Dranitsaris et al.38 |
| Vomiting | 1.7% | 3% | $1069 (inflated from 2006) | Tina Shih et al.39 |
| Herpes zosterb | NR | 0.3% | $1108 (inflated from 2008) | White et al.40 |
| Pneumonia | 8.5% | NR | $13,320 (inflated from 2006) | Eber et al.41 |
| Total AE management costs during median study period | $2243 | $460 | ||
| Treatment weeks (per protocol or to progression) | 52 | 27 | ||
| Total AE management costs per day | $6.16 | $2.44 | ||
a
Adjusted to reflect 75% reduction from prophylaxis.
b
All grades; adjusted to reflect 85% reduction from prophylaxis.